Ксизал (levocetirizine) is commonly used to support symptomatic relief across key allergic domains, generally helping to ease the overall symptom load for the patient. The medication is relevant across two main therapeutic areas, aligned with established clinical guidance: Allergic Rhinitis and Chronic Urticaria.

Symptom Management and Clinical Scenarios

The medication is used across domains where additional symptomatic support is needed to address conditions presenting with acute episodes or fluctuating symptom patterns. The primary indications are Allergic Rhinitis, encompassing both seasonal hay fever and year-round perennial symptoms, and the management of uncomplicated skin manifestations of Chronic Idiopathic Urticaria (CIU).

The medication helps address the classic cluster of symptoms, including frequent sneezing, runny nose, and nasal itching, and corresponding ocular manifestations like red, watery, and itchy eyes, alongside the pronounced pruritus (itching) associated with hives.

---

Quick Fact: Relief for Pronounced Symptoms

The medication is considered relevant for easing skin symptoms where intense pruritus is a dominant feature, and for managing symptoms that create noticeable functional strain from allergic rhinitis.

The eligibility for using Ксизал (levocetirizine) is strictly defined by regulatory documents based on underlying health conditions and age-specific safety profiles.

Eligibility Status	Applicable Populations
Contraindicated (Must Not Use)	Patients with known hypersensitivity to levocetirizine, cetirizine, or any piperazine derivative. Patients with end-stage renal disease (creatinine clearance < 10 mL/min) or who are undergoing dialysis. Children aged 6 months to 11 years with impaired renal function
Use Restricted/Conditional	Adults and adolescents with mild-to-moderate renal impairment require a specific dose adjustment determined by the degree of kidney function loss. Caution is advised for patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia) or a history of epilepsy or convulsions.

The medicine is not recommended for infants under 6 months of age, as safety and efficacy have not been established in this group. The tablet formulation is also not recommended for children under six years old. For pregnant or breastfeeding women, use is generally not recommended due to limited clinical data and the drug's excretion into human milk, respectively.

Interactions with other medicines and products

The interaction profile of Levocetirizine dihydrochloride is defined by potential additive effects on the central nervous system and specific alterations to drug clearance. All reported interactions are based strictly on regulatory labeling.

---

Pharmacodynamic and CNS Effects

Co-administration with alcohol or other Central Nervous System (CNS) depressants, such as sedatives or tranquilizers, may cause additive pharmacological effects. This combination is documented to result in further impairment of CNS performance and an additional reduction in alertness for sensitive patients. Due to this pharmacodynamic reinforcement, co-use with alcohol is a documented restriction.

---

Pharmacokinetic and Exposure Effects

Studies indicate a clinically significant pharmacokinetic interaction with ritonavir. Co-administration of the parent compound, cetirizine, with ritonavir resulted in a reduction in clearance and an increase in systemic exposure (Area Under the Curve, AUC). Levocetirizine is largely excreted unchanged by the kidneys, giving it a low potential for metabolic drug interactions involving major CYP enzymes.

---

Administration-Related Interactions

The administration of Levocetirizine with food does not alter the total extent of absorption (AUC). However, food decreases the rate of absorption, leading to a lower maximum plasma concentration (Cmax). Furthermore, since clearance is reduced in patients with renal impairment, this patient population requires specific consideration regarding overall drug exposure.

Targeted H₁ Receptor Blockade

---

The drug's primary action involves highly selective inverse agonism at the Histamine H₁ receptor on peripheral cell surfaces. It binds to the receptor, stabilizing it in an inactive conformation. This prevents the natural ligand, histamine, from binding and initiating its characteristic intracellular signaling cascade, thereby suppressing histamine-driven cellular activity in the targeted tissues.

---

Modulating Systemic Physiological Responses

The receptor blockade directly modifies the downstream effects of the histaminergic pathway. This includes suppressing the histamine-induced increase in vascular permeability and the associated dilation of small blood vessels. The mechanism restricts the extravasation of fluid into tissues and modulates the excitation of peripheral sensory nerve endings. This action shapes the drug’s overall physiological effect profile by interrupting the characteristic systemic consequences of H₁ receptor activation.

Ксизал (levocetirizine dihydrochloride) is administered exclusively through the oral route, utilizing dosage forms such as the 5 mg film-coated tablet or the oral solution/drops. The standard regimen for adults and adolescents aged 12 years and older involves a single dose of 5 mg once per day. A lower dose of 2.5 mg once daily may be used when deemed sufficient. The total daily dose should be taken in one single intake, and it is generally recommended that administration be conducted in the evening.

Administration can be performed with or without food. For the tablets, the 5 mg strength is scored, which facilitates the 2.5 mg dose when necessary. When using the liquid form, a calibrated measuring device must be employed to ensure the accuracy of the dose.

The dosing schedule is subject to modification based on specific patient populations. For children between 6 and 11 years, the labeled dose is 2.5 mg once daily. Critically, the dosing frequency and amount must be adjusted for patients with renal impairment, based on their creatinine clearance, with reduced doses ranging from 2.5 mg every other day to twice weekly. No dose adjustment is specified for isolated hepatic impairment. The duration of use is variable, ranging from short-term administration for acute episodes to continuous maintenance for persistent conditions.

Research Evidence / Overview of Studies for Ксизал

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research into Ксизал (levocetirizine) has largely centered on short-term, randomized controlled trials (RCTs). These studies typically compare the medication to a placebo or another active treatment, and this design is used in research exploring how symptoms change over time. The main focus was to monitor changes in Total Symptom Scores (TSS), which track specific symptoms like sneezing, runny nose, nasal itching, and ocular manifestations (itchy, watery eyes).

These studies were applied in studies examining patient-reported experiences in individuals with both Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR). The research explored short-term symptom changes over periods typically lasting from one to six weeks. However, the majority of the current evidence comes from these short-term studies, meaning long-term outcomes are not fully established beyond a few months. Furthermore, studies have noted variability in the measured outcome for nasal congestion, suggesting less consistency for this specific symptom compared to others.

---

Evidence for Use in Chronic Urticaria

The research structure for chronic urticaria, or chronic hives, includes randomized, placebo-controlled studies. These trials focused on outcomes linked to inflammatory or irritative states on the skin, specifically monitoring the reported intensity of pruritus (itching) and changes in the appearance and count of wheals (hives/lesions).

These studies were used in research exploring how symptoms change over time for individuals experiencing Chronic Spontaneous Urticaria (CSU), where symptoms may vary in intensity. Studies monitored how itching and wheal activity evolved in the observed populations over the typical study duration. Research has also explored the use of higher-than-standard doses in patients who did not have an initial measured response, though much of the data on this use is derived from smaller analyses. The evidence for long-term outcomes remains insufficient regarding the sustained stability of patterns over multiple years of ongoing treatment.

---

What is Still Uncertain About Ксизал

• Follow-up durations were limited across the primary efficacy trials, meaning there is limited information for long-term outcomes or the stability of observed patterns after many months of use.
• Data for certain groups remain insufficient, including evidence from controlled trials for very young children (under age 6) and from large-scale studies specifically addressing older adults or individuals with multiple complex health issues.

Common questions about Ксизал (FAQ)

Q: How quickly can I expect Ксизал to start working?

A: According to the official product information, the onset of action in controlling pollen-induced symptoms has been observed to occur at 1 hour after taking the medication in placebo-controlled trials. This indicates that symptom management has been observed to start soon after the first dose.

Q: How long does the effect of one tablet of Ксизал typically last?

A: Research has shown that the drug's effect on certain histamine-induced skin reactions lasts for 24 hours. The standard regimen is a single dose once per day, and this is intended to cover a 24-hour period.

Q: Does Ксизал cause drowsiness or make you sleepy?

A: The most common adverse reactions reported in clinical trials include somnolence (drowsiness) and fatigue. Due to the potential for reduced alertness, official information indicates caution is advised when performing tasks that require complete mental awareness, such as driving or operating machinery.

Q: Can Ксизал be taken at the same time as cold or flu remedies?

A: Official regulatory documents advise caution when combining this medication with central nervous system (CNS) depressants. This is because the combination may cause an additive pharmacological effect, leading to further impairment of alertness. It is advised to use caution with any combination that may increase drowsiness.

Q: Can I take Ксизал if I have kidney problems?

A: The medication is contraindicated, meaning it must not be used, in patients with end-stage renal disease or those undergoing dialysis. For individuals with mild-to-moderate kidney impairment, official product information indicates that the dosing regimen requires adjustment based on the degree of kidney function loss.

Q: If I have liver issues, can I safely use Ксизал?

A: No dose adjustment is specified for patients with solely hepatic impairment (liver issues) in the official prescribing information. However, official product information recommends a dose adjustment for patients who have both hepatic and renal (kidney) impairment.

Q: Is the onset of action faster for the liquid form of Ксизал compared to the tablet form?

A: In studies involving healthy adult subjects, the oral solution achieved mean peak plasma concentrations approximately 0.4 hours faster than the tablet formulation. This difference in time to peak plasma concentrations is documented in studies.

Q: What does official guidance say about using Ксизал during pregnancy?

A: Use during pregnancy is generally not recommended due to limited clinical data on its effects. Due to limited clinical data, official guidance indicates the importance of consulting a healthcare professional before use.

Q: What does official guidance say about using Ксизал while breastfeeding?

A: Use while breastfeeding is generally not recommended because the drug is known to be excreted into human milk. Official guidance indicates the importance of consulting a healthcare professional before use during this period.

Q: Is it true that Ксизал is sometimes described as a 'non-sedating' antihistamine?

A: The medication is classified as a second-generation antihistamine, which are known to be generally less sedating than older, first-generation compounds. However, official safety data still lists drowsiness (somnolence) as a common adverse reaction that may affect some users.

Q: Are there any common foods or drinks that should be avoided when taking Ксизал?

A: Regulatory documents specifically advise avoiding alcohol while using this medication due to the potential for increased central nervous system impairment. Food itself may slightly slow the rate of absorption but does not affect the overall amount of drug absorbed.

Q: What happens if I accidentally take two doses of Ксизал close together?

A: In the event that more than the recommended amount is taken, official guidance is to contact a healthcare professional or Poison Control Center immediately. It is also advised not to take a double dose to compensate for a previously missed dose.

Q: What should I do if I forget to take my daily dose of Ксизал?

A: According to regulatory sources, if a dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped and the regular schedule resumed. The instructions indicate not to take a double dose.

Q: Does Ксизал interact with common pain relievers like ibuprofen or acetaminophen?

A: Certain pain relief products that contain central nervous system (CNS) depressants may have an additive effect and increase the risk of sedation when taken with this medication. It is advised to be cautious with any combination that may increase drowsiness.

Q: Are there any documented cases of long-term side effects from using Ксизал?

A: The FDA has required a warning that severe itching (pruritus) has been reported in patients who stop taking the drug after long-term daily use. This effect can occur within a few days after stopping the medication.

Q: Can Ксизал be used to treat skin rashes or hives (urticaria)?

A: The medication is indicated for the symptomatic relief of the uncomplicated skin manifestations of chronic idiopathic urticaria, which is commonly known as chronic hives. Its action is designed to reduce the itching and wheal formation associated with this condition.

Q: What distinguishes Ксизал from older generation allergy medications?

A: The medication is classified as a second-generation antihistamine. Chemically, it is the single active form (R-enantiomer) of the related drug cetirizine, a structure associated with a high affinity for H1-receptors and generally lower rates of sedation than older compounds.

Q: Is there any research on the effectiveness of Ксизал for indoor vs. outdoor allergies?

A: The medication is indicated for the treatment of symptoms associated with both seasonal allergic rhinitis (often triggered by outdoor allergens like pollen) and perennial allergic rhinitis (often triggered by indoor allergens like dust mites).

Q: Is there a generic version of Ксизал available?

A: Yes, the active ingredient, levocetirizine dihydrochloride, is available from various manufacturers as a generic product. Regulatory documents list the generic formulation alongside the brand name product.

Q: Is there a maximum recommended period for continuous use of Ксизал?

A: Clinical experience has been documented for continuous treatment periods up to 6 months with the 5 mg film-coated tablet formulation in patients being treated for persistent allergic rhinitis.

Q: Does taking Ксизал affect blood pressure?

A: While not a common side effect, severe hypotension (low blood pressure) has been reported in post-marketing experience with the related compound, cetirizine. This is noted as a potential adverse event that may also occur with levocetirizine.

Q: What type of research evidence supports the use of Ксизал for perennial rhinitis?

A: The efficacy and safety of the medication for perennial allergic rhinitis are supported by data gathered from double-blind, placebo-controlled clinical trials. These studies are used to confirm how well the medication works compared to an inactive substance.

Q: Does Ксизал contain gluten or lactose?

A: The inactive ingredients listed in the official product information for the film-coated tablet formulation include lactose monohydrate.

Q: Are there any reports of weight gain associated with the use of Ксизал?

A: Weight increase is listed as a rare adverse event in the official safety profile based on clinical experience. It is listed as a rare event.

Q: Are there official statements regarding the risk of dependence or withdrawal with Ксизал?

A: Official warnings have been added regarding the risk of severe itching (pruritus) that may occur within a few days after stopping the drug following long-term use. This should be distinguished from dependence.

Q: Does Ксизал affect the immune system directly?

A: The primary mechanism is selective antagonism of the H1-receptor, which manages the symptoms of the allergic response. However, clinical studies have shown the medication to inhibit the migration of eosinophils, a type of white blood cell involved in allergic inflammation.

Q: What types of allergic reactions (beyond typical symptoms) are listed as potential side effects?

A: Severe hypersensitivity reactions are described in the official safety profile. These include anaphylaxis and angioedema, which are serious and documented as adverse reactions.

Q: What is the general eligibility requirement for someone to use Ксизал?

A: General eligibility is defined by the need for symptomatic relief of allergic conditions, provided the patient does not have a contraindication. Contraindications include a known hypersensitivity to the drug or severe kidney impairment.

Q: Do studies suggest Ксизал is effective for dust mite allergies?

A: Yes, a clinical study examining persistent allergic rhinitis (a chronic condition often caused by indoor allergens) included adult patients who were sensitized to house dust mites and grass pollen. The medication is indicated for this type of rhinitis.

How to Store and Dispose of Xyzal (Levocetirizine Dihydrochloride)

The storage and disposal of Xyzal must adhere strictly to the conditions specified in the official regulatory labeling to ensure product stability and safety.

---

Official Storage Requirements

Formulation	Mandatory Temperature	Environmental Protection
Tablets	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)	Store in original packaging.
Oral Solution/Drops	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)	Keep in original package to protect from light.

The oral solution and drops must be discarded 3 months after the container is first opened.

Child Safety and Disposal

All forms of Xyzal must be kept out of the sight and reach of children. Unused or expired medication must not be disposed of by flushing it down a toilet or sink, nor should it be thrown in household trash. Disposal should follow local regulations, often requiring return to a pharmacy or using an official drug take-back program.